Professor Cummings is a world-renowned neurologist. He has received the Bengt Winblad Lifetime Achievement Award from the national Alzheimer’s Association for his outstanding research and leadership contributions. He is also Founding Director, Cleveland Clinic Lou Ruvo Center for Brain Health.
Prof. GENG is a doctorial tutor and key inventor of GV-971. She is titled as principal investigator and Academic Director General of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. She is also Chief Scientist of a national project for glycobiology and carbohydrate chemistry study (called as ‘973 Program’). Dr. Geng’s research is focused on the discovery and development of targeted therapies for both Alzheimer's disease and cancer, incl. biomarker discovery. She has published more than 180 research articles in peer-review journals including Cell, Cancer Cell, Cell Res, J Natl Cancer Inst, Nature Commun, Hepatology, Cancer Res etc.
Prof. Philip Scheltens was Scientific Director of the Dutch Pearlstring Institute (PSI) and was appointed Vice President of the board of the Dutch “Deltaplan Dementia”. He is active in the field of biomarkers and clinical trials and has been the (inter) national PI for many studies, including Phase I–III multicentre clinical trials.
Dr. Reiman is internationally recognized for his contributions to brain imaging research, the behavioral neurosciences and the study of Alzheimer’s disease. He is a recipient of the Potamkin Prize for his pioneering contributions to the unusually early detection of Alzheimer’s disease and the accelerated evaluation of prevention therapies.
The Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS) is one of the most advanced Chinese research institutions for drug discovery with a sublime international reputation. Green Valley has built a long-term, strategic, cooperative relationship with SIMM. As a result, the Green Valley Innovation Fund was specifically established to enhance the creation of industry innovation and the realization of scientific research achievements.
Bracket is an American company that operates internationally that specializes in the training of scale rater consistency. Green Valley leverages the professional experience of Bracket in scale evaluations to conduct unified training and evaluation of scale raters participating clinical trials.
Based in the United Kingdom, IXICO is a public company devoted to the data collection, quality control and analytical services of medical imaging. Green Valley cooperates with IXICO in calibrating the PET of clinical research centers and training imaging technicians in a standardized manner. This is obviously done to control the collected data quality and analysis.
Banner Alzheimer's Institute enjoys great fame in America as well as the rest of the world. It is committed to promulgating new care standards for AD patients and their family members. Banner is a leading innovative research institute specializing in the detection and treatment of AD. Green Valley has invited experts from the Banner Alzheimer's Institute to provide academic support for its AD drug research.
Green Valley has joined hands with experts from top institutions of higher learning such as the University of Washington, Rowan University, and the University of Toronto. Green Valley, along with these Institutions have conducted research projects and developed biomarker applications which utilize non-invasive detection methods.
Quintiles is the largest pharmaceutical and bio-technology service provider in the world. Green Valley has built a long-term, strategic cooperation with Quintiles to gain access to a one-stop clinical research service which supports new drug R&D all over the world.
Covance is a world-renowned pharmaceutical and bio-technology service provider. Covance has provided comprehensive biological sample GLP testing services for Green Valley during their strategic collaboration.
JOINN is a famous Chinese pharmaceutical and bio-technology service provider. Green Valley has engaged in a multi-dimensional cooperation with JOINN that has produced beneficial results in terms of drug safety evaluation, drug screening, and pharmacokinetics research, etc.